{"filing":{"accession_number":"0001437749-26-026790","cik":"0001401040","ticker":"DMAC","company_name":"DiaMedica Therapeutics Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"dmtp20260809_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1401040/000143774926026790/dmtp20260809_8k.htm"},"events":[{"id":26668,"run_id":24241,"accession_number":"0001437749-26-026790","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"DiaMedica disclosed its condensed consolidated financial results for the quarter ended June 30, 2026, via a press release attached as Exhibit 99.1. The filing includes quarterly financial metrics (cash position of $43.5 million, net losses of $10.1 million and $20.2 million for Q2 and six months respectively), operating cash flows, and expense breakdowns by category (R\u0026D, G\u0026A). This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and runway.","company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27873,"accession_number":"0001437749-26-026790","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"DiaMedica disclosed its condensed consolidated financial results for the quarter ended June 30, 2026, via a press release attached as Exhibit 99.1. The filing includes quarterly financial metrics (cash position of $43.5 million, net losses of $10.1 million and $20.2 million for Q2 and six months respectively), operating cash flows, and expense breakdowns by category (R\u0026D, G\u0026A). This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:39:11.544937+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27873,"accession_number":"0001437749-26-026790","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"DiaMedica disclosed its condensed consolidated financial results for the quarter ended June 30, 2026, via a press release attached as Exhibit 99.1. The filing includes quarterly financial metrics (cash position of $43.5 million, net losses of $10.1 million and $20.2 million for Q2 and six months respectively), operating cash flows, and expense breakdowns by category (R\u0026D, G\u0026A). This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:39:11.544937+00:00","company_name":"DiaMedica Therapeutics Inc.","ticker":"DMAC","filing_date":"2026-08-10"}]}